| A comprehensive review on MAPK: a promising therapeutic target in cancer C Braicu, M Buse, C Busuioc, R Drula, D Gulei, L Raduly, A Rusu, A Irimie, ... Cancers 11 (10), 1618, 2019 | 690 | 2019 |
| Progresses towards safe and efficient gene therapy vectors S Chira, CS Jackson, I Oprea, F Ozturk, MS Pepper, I Diaconu, C Braicu, ... Oncotarget 6 (31), 30675, 2015 | 256 | 2015 |
| Overview upon miR-21 in lung cancer: focus on NSCLC C Bica-Pop, R Cojocneanu-Petric, L Magdo, L Raduly, D Gulei, ... Cellular and Molecular Life Sciences 75, 3539-3551, 2018 | 210 | 2018 |
| Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers R Cojocneanu Petric, C Braicu, L Raduly, O Zanoaga, N Dragos, ... OncoTargets and therapy, 2053-2066, 2015 | 96 | 2015 |
| The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression D Gulei, L Magdo, A Jurj, L Raduly, R Cojocneanu-Petric, A Moldovan, ... Cell Death & Disease 9 (2), 66, 2018 | 86 | 2018 |
| Implications of dietary ω‑3 and ω‑6 polyunsaturated fatty acids in breast cancer O Zanoaga, A Jurj, L Raduly, R Cojocneanu‑Petric, E Fuentes‑Mattei, ... Experimental and therapeutic medicine 15 (2), 1167-1176, 2018 | 84 | 2018 |
| SERS-based differential diagnosis between multiple solid malignancies: Breast, colorectal, lung, ovarian and oral cancer V Moisoiu, A Stefancu, D Gulei, R Boitor, L Magdo, L Raduly, S Pasca, ... International journal of nanomedicine, 6165-6178, 2019 | 67 | 2019 |
| Spontaneous and induced animal models for cancer research A Onaciu, R Munteanu, VC Munteanu, D Gulei, L Raduly, RI Feder, ... Diagnostics 10 (9), 660, 2020 | 61 | 2020 |
| Inhibitory effect of CAPE and kaempferol in colon cancer cell lines—possible implications in new therapeutic strategies L Budisan, D Gulei, A Jurj, C Braicu, O Zanoaga, R Cojocneanu, L Pop, ... International journal of molecular sciences 20 (5), 1199, 2019 | 53 | 2019 |
| Aberrant miRNAs expressed in HER-2 negative breast cancers patient C Braicu, L Raduly, G Morar-Bolba, R Cojocneanu, A Jurj, LA Pop, ... Journal of Experimental & Clinical Cancer Research 37, 1-16, 2018 | 51 | 2018 |
| Plasma and tissue specific miRNA expression pattern and functional analysis associated to colorectal cancer patients R Cojocneanu, C Braicu, L Raduly, A Jurj, O Zanoaga, L Magdo, A Irimie, ... Cancers 12 (4), 843, 2020 | 47 | 2020 |
| miR‐181a/b therapy in lung cancer: reality or myth? C Braicu, D Gulei, R Cojocneanu, L Raduly, A Jurj, E Knutsen, GA Calin, ... Molecular oncology 13 (1), 9-25, 2019 | 45 | 2019 |
| The extensive role of miR-155 in malignant and non-malignant diseases D Gulei, L Raduly, E Broseghini, M Ferracin, I Berindan-Neagoe Molecular aspects of medicine 70, 33-56, 2019 | 43 | 2019 |
| Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression C Braicu, R Buiga, R Cojocneanu, M Buse, L Raduly, LA Pop, S Chira, ... Journal of Experimental & Clinical Cancer Research 38, 1-17, 2019 | 41 | 2019 |
| The relevance of mass spectrometry analysis for personalized medicine through its successful application in cancer “Omics” CA Ciocan-Cartita, A Jurj, M Buse, D Gulei, C Braicu, L Raduly, ... International Journal of Molecular Sciences 20 (10), 2576, 2019 | 37 | 2019 |
| Cannabidiol and vitamin D3 impact on osteogenic differentiation of human dental mesenchymal stem cells NB Petrescu, A Jurj, O Sorițău, OP Lucaciu, N Dirzu, L Raduly, ... Medicina 56 (11), 607, 2020 | 26 | 2020 |
| Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms C Braicu, D Gulei, L Raduly, A Harangus, A Rusu, I Berindan-Neagoe Molecular aspects of medicine 70, 90-105, 2019 | 26 | 2019 |
| New insights in gene expression alteration as effect of paclitaxel drug resistance in triple negative breast cancer cells A Jurj, LA Pop, O Zanoaga, CA Ciocan-Cârtiţă, R Cojocneanu, ... Cell. Physiol. Biochem 54 (4), 648-664, 2020 | 23 | 2020 |
| Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma A Baritchii, A Jurj, O Soritau, C Tomuleasa, L Raduly, O Zanoaga, ... J buon 21 (1), 199-207, 2016 | 23 | 2016 |
| New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells CA Ciocan-Cartita, A Jurj, O Zanoaga, R Cojocneanu, LA Pop, ... Journal of Experimental & Clinical Cancer Research 39, 1-16, 2020 | 22 | 2020 |
